ALK and neuroblastoma: Activating mutations of anaplastic lymphoma kinase (ALK) or amplifications of the ALK gene, found in >10–15% of high-risk neuroblastomas, are correlated with adverse outcomes, but also define a potential target for a molecular-targeted therapy with ALK inhibitors [19,20,21,22,23,24,25,26].